Evidence grade: WEAK — Supported only by weak or preliminary evidence.
MGMT governs temozolomide benefit; a false imaging surrogate could misdirect therapy or stratification, yet the task keeps being re-attempted.
Reported AUCs 0.7-0.9 vs rigorous studies finding no reliable MRI-MGMT correlation and attributing success to leakage.
Definitive multi-institutional external test with leakage audit and pre-registered analysis; publish a negative/limits result if warranted.
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.